Evidence map›Paper›PMID 41313652›Full record

ArticlePacing and clinical electrophysiology : PACE2026

Predictors of Atrial High-Rate Episodes and Inappropriate Device Therapy in Implantable Cardioverter Defibrillators.

Marthe J Huntelaar, Luuk H G A Hopman, Anne-Lotte C J van der Lingen, Mischa T Rijnierse, Michiel J B Kemme, Cornelis P Allaart, Vokko P van Halm

Abstract read
In one paragraph

Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marthe J HuntelaarDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.ORCID 0009-0002-9557-1692
Luuk H G A HopmanDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.ORCID 0000-0002-3896-9920
Anne-Lotte C J van der LingenDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
Mischa T RijnierseDepartment of Cardiology, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.
Michiel J B KemmeDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
Cornelis P AllaartDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
Vokko P van HalmDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImplantable cardioverter defibrillator (ICD) therapy can prevent sudden cardiac death, but poses a risk of inappropriate device therapy (IDT), which is linked to worse outcomes and reduced quality of life. On the other hand, ICDs can function as an early warning system for atrial arrhythmias. PURPOSE: This study aimed to predict which patients are at risk of IDT and who develop atrial high-rate episodes (AHRE) by investigating pre-implant clinical parameters.

methodsPatients who received an ICD with an atrial lead between 2010 and 2019 were included in a prospective registry.

resultsOver 5.3 ± 3.0 years, 136 of 413 patients received appropriate device therapy, and 36 patients received IDT. Univariate cox regression analyses on 40 parameters were performed, followed by forward multivariate cox regression. The best predictive model (Harrell's C-index 0.785) included secondary prevention ICD, ischemic CMP (iCMP), CMP not classified as ischemic, hypertrophic or dilated (uCMP), and diuretic use as risk factors, with mineralocorticoid receptor-antagonists (MRA) use and diabetes as protective factors. Surprisingly, AF was not a predictor of IDT. Among 313 patients without prior AF, 136 developed AHRE. Similar cox regressions predicted AHRE development, resulting in a model (Harrell's C-index 0.663) based on age, left ventricular ejection fraction (LVEF), hypertrophic CMP (hCMP), family history of cardiovascular disease (CVD), and hypercholesterolemia.

conclusionThis study identified six factors that influence the risk of IDT, and five other factors as risk factors for developing AHRE. Pre-implant assessment of these variables can help to better inform patients of the potential benefits and risks.

Indexed as

Atrial FibrillationDefibrillators, ImplantableAgedDeath, Sudden, CardiacFemaleHumansMaleMiddle AgedProspective StudiesRegistriesRisk Factorsatrial high‐rate episodesimplantable cardioverter defibrillatorinappropriate device therapy

Identifiers

PMID41313652
PMCPMC12873501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.